Trinity Biotech (TRIB) Cash & Equivalents (2016 - 2024)
Trinity Biotech (TRIB) has disclosed Cash & Equivalents for 9 consecutive years, with $5.2 million as the latest value for Q4 2024.
- Quarterly Cash & Equivalents rose 39.99% to $5.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2024, up 39.99% year-over-year, with the annual reading at $5.2 million for FY2024, 39.99% up from the prior year.
- Cash & Equivalents hit $5.2 million in Q4 2024 for Trinity Biotech, up from $3.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $27.3 million in Q4 2020 to a low of $3.7 million in Q4 2023.
- Historically, Cash & Equivalents has averaged $13.7 million across 5 years, with a median of $6.6 million in 2022.
- Biggest five-year swings in Cash & Equivalents: surged 66.63% in 2020 and later tumbled 74.61% in 2022.
- Year by year, Cash & Equivalents stood at $27.3 million in 2020, then decreased by 5.19% to $25.9 million in 2021, then crashed by 74.61% to $6.6 million in 2022, then crashed by 43.89% to $3.7 million in 2023, then surged by 39.99% to $5.2 million in 2024.
- Business Quant data shows Cash & Equivalents for TRIB at $5.2 million in Q4 2024, $3.7 million in Q4 2023, and $6.6 million in Q4 2022.